Search
forLearn
5 / 801 resultslearn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn Tricopper peptides
learn copper tripeptide-1
learn multipeptides
Research
5 / 1000+ resultsresearch Distribution of P2X3‐immunoreactive fibers in hairy and glabrous skin of the rat
P2X3-IR fibers are widespread in rat skin and likely help detect pain.
research Therapeutic Effect of Platelet-Rich Plasma Improves Bladder Overactivity in the Pathogenesis of Ketamine-Induced Ulcerative Cystitis in a Rat Model
Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.
research Examples of Clinical Use of Botulinum Toxin: A Literature Review
Botulinum toxin is effectively used to treat various painful conditions and its therapeutic uses are growing.
research Immunohistochemical expressions of mGluR5, P2Y2 receptor, PLC-?1, and IP3R-I and -II in Merkel cells in rat sinus hair follicles
research Peripheral patterns of calcitonin‐gene‐related peptide general somatic sensory innervation: Cutaneous and deep terminations
CGRP-IR axons may help maintain and renew tissues.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Setipiprant/PGE2 feedbacks?
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
community Phase 3 of pyrilutamide (kx-836) analysis of the efficacy
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.